Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 9/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2233136 | 1.00 | GPR183 (0.49) | GPR183MEN1KMT2AACHEENPP2 | |
| Hydrochloric Acid SCHEMBL13582203 | 0.99 | GPR183 (0.49) | GPR183MEN1KMT2AACHEENPP2 | |
| Hydrochloric Acid SCHEMBL2230736 | 0.99 | GPR183 (0.49) | GPR183MEN1KMT2AACHEENPP2 | |
| SCHEMBL2234532 | 0.98 | GPR183 (0.51) | GPR183MEN1KMT2AACHEENPP2 | |
| SCHEMBL2234529 | 0.98 | GPR183 (0.51) | GPR183MEN1KMT2AACHEENPP2 | |
| Hydrochloric Acid SCHEMBL2297909 | 0.97 | GPR183 (0.47) | GPR183MEN1KMT2AACHEENPP2 | |
| Hydrochloric Acid SCHEMBL2297903 | 0.97 | GPR183 (0.47) | GPR183MEN1KMT2AACHEENPP2 | |
| Hydrochloric Acid SCHEMBL2232308 | 0.97 | GPR183 (0.51) | GPR183MEN1KMT2AACHEENPP2 | |
| Hydrochloric Acid SCHEMBL2232302 | 0.97 | GPR183 (0.51) | GPR183MEN1KMT2AACHEENPP2 | |
| SCHEMBL2233650 | 0.96 | GPR183 (0.46) | GPR183MEN1KMT2AACHEENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858455-B2 | Process for the production of water and solvent-free nitrile rubbers | ARLANXEO DEUTSCHLAND GMBH (DE) | 2020-12-08 | — | — | US | disclosed |
| EP-3148693-B1 | CYCLIC BENT ALLENE METAL COMPLEXES | GOVERNING COUNCIL UNIV TORONTO (CA) | 2019-07-17 | — | — | EP | disclosed |
| US-10253055-B2 | Ruthenium-based triazole carbene complexes | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2019-04-09 | — | — | US | disclosed |
| US-9920086-B2 | Ruthenium-based complexes, their preparation and use as catalysts | ARLANXEO DE GMBH (DE) | 2018-03-20 | — | — | US | disclosed |
| US-9738671-B2 | Cyclic bent allene metal complexes | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-08-22 | — | — | US | disclosed |
| US-20170137448-A1 | CYCLIC BENT ALLENE METAL COMPLEXES | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-05-18 | — | — | US | disclosed |
| EP-3148693-A1 | CYCLIC BENT ALLENE METAL COMPLEXES | The Governing Council of the University of Toronto (CA) | 2017-04-05 | — | — | EP | disclosed |
| EP-3134206-A1 | RUTHENIUM-BASED TRIAZOLE CARBENE COMPLEXES | The Governing Council of the University of Toronto (CA) | 2017-03-01 | — | — | EP | disclosed |
| US-20170044195-A1 | RUTHENIUM-BASED TRIAZOLE CARBENE COMPLEXES | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-02-16 | — | — | US | disclosed |
| EP-3116915-A1 | PROCESS FOR THE PREPARATION OF POLYMERS CONTAINING AMINO GROUPS EMPLOYING A HETEROGENEOUS IRON CATALYST | ARLANXEO Deutschland GmbH (DE) | 2017-01-18 | — | — | EP | disclosed |
| US-9023914-B2 | Nitrile rubbers and production thereof in organic solvents | LANXESS DEUTSCHLAND GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| EP-2528897-B9 | DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMA CO LTD (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2528897-B1 | DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMA CO LTD (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8722663-B2 | Di-substituted pyridine derivatives as anticancers | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-05-13 | — | — | US | disclosed |
| WO-2013098056-A1 | PURIFICATION OF OPTIONALLY HYDROGENATED NITRILE RUBBER | LANXESS DEUTSCHLAND GMBH (DE) | 2013-07-04 | — | — | WO | disclosed |
| EP-2528897-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2012-12-05 | — | — | EP | disclosed |
| US-20120283351-A1 | NITRILE RUBBERS AND PRODUCTION THEREOF IN ORGANIC SOLVENTS | LANXESS DEUTSCHLAND GMBH (DE) | 2012-11-08 | — | — | US | disclosed |
| US-20120283242-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-11-08 | — | — | US | disclosed |
| WO-2011093524-A9 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011093524-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253055-B2 | Ruthenium-based triazole carbene complexes | HIRIP3, GTF2I, GTF3C5 | GPR183 1725/4885MEN1 4557/4885KMT2A 4093/4885 |
| US-20170137448-A1 | CYCLIC BENT ALLENE METAL COMPLEXES | AP2M1, AP2A2, AP2A1 | GPR183 3508/4885MEN1 2807/4885KMT2A 1943/4885 |
| US-20170044195-A1 | RUTHENIUM-BASED TRIAZOLE CARBENE COMPLEXES | HIRIP3, GTF2I, GTF3C5 | GPR183 1725/4885MEN1 4557/4885KMT2A 4093/4885 |
| US-20120283242-A1 | DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS | TPD52L2, CCNE2, CDK2 | GPR183 1249/4885MEN1 2854/4885KMT2A 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.